- Home
- MEDP vs NBIX Comparison
MEDP vs NBIX Comparison
Compare MEDP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- NBIX
- Stock Information
- Founded
- MEDP 1992
- NBIX 1992
- Country
- MEDP United States
- NBIX United States
- Employees
- MEDP N/A
- NBIX N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEDP Health Care
- NBIX Health Care
- Exchange
- MEDP Nasdaq
- NBIX Nasdaq
- Market Cap
- MEDP 11.7B
- NBIX 11.8B
- IPO Year
- MEDP 2016
- NBIX 1996
- Fundamental
- Price
- MEDP $311.80
- NBIX $117.44
- Analyst Decision
- MEDP Buy
- NBIX Buy
- Analyst Count
- MEDP 10
- NBIX 24
- Target Price
- MEDP $388.44
- NBIX $163.91
- AVG Volume (30 Days)
- MEDP 442.3K
- NBIX 1.0M
- Earning Date
- MEDP 10-21-2024
- NBIX 10-30-2024
- Dividend Yield
- MEDP N/A
- NBIX N/A
- EPS Growth
- MEDP 33.84
- NBIX 97.40
- EPS
- MEDP 11.42
- NBIX 3.73
- Revenue
- MEDP $2,070,866,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- MEDP $14.01
- NBIX $26.97
- Revenue Next Year
- MEDP $5.86
- NBIX $16.69
- P/E Ratio
- MEDP $27.19
- NBIX $31.50
- Revenue Growth
- MEDP 16.24
- NBIX 25.72
- 52 Week Low
- MEDP $268.80
- NBIX $108.14
- 52 Week High
- MEDP $459.77
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- MEDP 40.35
- NBIX 42.69
- Support Level
- MEDP $356.36
- NBIX $119.08
- Resistance Level
- MEDP $366.98
- NBIX $129.67
- Average True Range (ATR)
- MEDP 12.77
- NBIX 3.34
- MACD
- MEDP 0.39
- NBIX -0.02
- Stochastic Oscillator
- MEDP 17.30
- NBIX 14.59
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.